A New Way to Study Cytokine Release Syndrome

In vivo CRS assays have the potential to simultaneously derisk and accelerate the process of bringing successful therapies to the patients who need them most. Not only can drug developers avoid bringing dangerous compounds into the clinic, they can also pour more resources into promising candidates to bypass bottlenecks, optimize final products, and bring them to market.

While testing immunomodulatory therapies is the most obvious initial use for in vivo CRS assays, this humanized mouse platform has far-reaching potential applications. For example, this model could offer insight into underlying biological differences that predispose some individuals to develop CRS after exposure to certain infectious diseases. The researchers of today can be part of unlocking the possibilities of tomorrow for CRS assessment and more. With these tools at our disposal, let’s do better, together.